Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Non Operating Income (2016 - 2025)

IGC Pharma (IGC) has disclosed Non Operating Income for 12 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • Quarterly Non Operating Income rose 2406.98% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, up 1548.0% year-over-year, with the annual reading at $325000.0 for FY2025, 127.27% up from the prior year.
  • Non Operating Income for Q3 2025 was $1.1 million at IGC Pharma, up from $306000.0 in the prior quarter.
  • The five-year high for Non Operating Income was $1.1 million in Q3 2025, with the low at $4000.0 in Q3 2021.
  • Average Non Operating Income over 5 years is $127631.6, with a median of $32000.0 recorded in 2023.
  • The sharpest move saw Non Operating Income crashed 96.16% in 2022, then skyrocketed 2971.43% in 2025.
  • Over 5 years, Non Operating Income stood at $4000.0 in 2021, then skyrocketed by 625.0% to $29000.0 in 2022, then rose by 10.34% to $32000.0 in 2023, then surged by 53.12% to $49000.0 in 2024, then skyrocketed by 2100.0% to $1.1 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $1.1 million, $306000.0, and $215000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.